Remove 2016 Remove Leads Remove Physicians
article thumbnail

The Bus, The Car and The Bike: Explaining Intersectionality

InCrowd

I often use myself as an example; I am a Latina, immigrant, young physician, all identities for which I need to pay a price and fight the biases associated with each. In addition, as a physician under 40 years old, I often encounter scenarios in which I am told, “you are too young to know,” we will call this the age tax.

article thumbnail

HeartBeam Announces Acquisition of LIVMOR Assets

Legacy MEDSearch

Founded in 2016, LIVMOR developed the Halo+ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Female Providers, A Unique Perspective: Part 2

InCrowd

I work with an older male physician colleague who lamented the loss of the family doctor, available nearly 7 days a week at all hours to his patients. of physicians were over the age of 55, an increase from 37.6% During this same time frame, the percentage of practicing female physicians rose from 28.3% In 2019, 44.9%

article thumbnail

Leading in Pharma: a woman’s pathway

European Pharmaceutical Review

She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member. I am a physician by training, and I worked in New York hospital emergency rooms for many years.

Leads 52
article thumbnail

Improving trial predictability: leveraging AI-powered analytics to guide trial design, strategy, and operations

pharmaphorum

Protocol design factors leading to operational challenges include design consistency, patient burden, site burden, study complexity, and eligibility criteria, including diversity and inclusion requirements. These potential study risks can lead to costly deviations and amendments, enrolment difficulties, and reduced patient compliance.

Leads 98
article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

However, it has taken over six years for Amjevita to launch, after first being FDA-approved in 2016. Many other biosimilars have also been FDA-approved since 2016. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

Placing clinicians at financial risk for controlling health costs and improving quality without equipping them with the tools to do so leads to frustration and disillusionment. Physicians dislike being outliers and adjust their practice patterns to conform when provided with a relative social ranking. million on orthopedic MS-DRGs.[1]